Abstract 3984
Background
Studies describe that up to 90 % of all patients develop chemotherapy induced peripheral neuropathy (CIPN) during and after treatment for colorectal cancer with the chemotherapeutic drug oxaliplatin. Patients may struggle with CIPN many years after treatment completion, and in worst case live with it permanently with deep impact on their everyday life. Until date, there is no treatment to prevent or treat CIPN. Thus, it is urgent to understand the influence of CIPN and detect early signs of this side effect. Still, no golden standard method of assessment and evaluation of CIPN exists. The study aims to answer: 1. What questionnaire is deemed suitable by patients and nurses regarding reporting and sharing the experience of side effects during and after oxaliplatin treatment? 2. How does chemotherapy CIPN progresses and impact everyday life among patients receiving oxaliplatin from initiation of adjuvant chemotherapy until 3 years follow up? 3. How do patients experience and cope with CIPN and how does it influence on their perception of body and self in everyday life during and after adjuvant chemotherapy for colorectal cancer?
Methods
The study applies a multi-methods design. To ensure the practicability and meaningfulness of the questionnaire, the questionnaire are chosen in collaboration with patients and nurses in the clinical setting. Two questionnaires are tested; functional assessment of cancer treatment gynecological oncology group neurotoxicity (FACT/GOG-Ntx) and Oxaliplatin associated neurotoxicity questionnaire (OANQ). To explore a more precise and a common understanding and perception of the grade of CIPN, a three-year follow up with the chosen questionnaires will be conducted. The patients’ experiences of side effects are explored within a phenomenological frame of reference and individual in-depth interviews.
Results
The study contributes to identification of early and late signs of CIPN and provides insight into the challenges patients experience. It may assist healthcare providers to address the specific needs of these patients.
Conclusions
The study is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Marlene Ægidiussen Jensen.
Funding
The Novo Nordisk Foundation - Nursing research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2152 - Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations
Presenter: Istvan Miklos
Session: Poster Display session 3
Resources:
Abstract
4382 - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs
Presenter: Alberto Rodrigo
Session: Poster Display session 3
Resources:
Abstract
2465 - Towards a screening test for cancer by circulating DNA analysis
Presenter: Rita Tanos
Session: Poster Display session 3
Resources:
Abstract
3788 - Evaluation of a successful launch of the MammaPrint and BluePrint NGS kit
Presenter: Leonie Delahaye
Session: Poster Display session 3
Resources:
Abstract
3863 - Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning
Presenter: Pierre Heudel
Session: Poster Display session 3
Resources:
Abstract
1993 - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα
Presenter: Na Li
Session: Poster Display session 3
Resources:
Abstract
4281 - CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?——A multi-center prospective study in China
Presenter: Jun Luo
Session: Poster Display session 3
Resources:
Abstract
2268 - Classification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer
Presenter: Shinsuke Sasada
Session: Poster Display session 3
Resources:
Abstract
4035 - Prediction of benign and malignant breast masses using digital mammograms texture features
Presenter: Cui Yanhua
Session: Poster Display session 3
Resources:
Abstract
5678 - Nanomaterials Augmented LDI-TOF-MS for Hepatocellular Carcinoma Diagnosis and Classification
Presenter: Jian Zhou
Session: Poster Display session 3
Resources:
Abstract